SurModics continues acquisition trail:
This article was originally published in Clinica
Executive Summary
Provider of drug delivery technology SurModics has closed its second acquisition of the month, after purchasing BioFX Laboratories in deal worth up to $22.7m. The Eden Prairie, Minnesota-based company bought Brookwood Pharmaceuticals on August 1 (see Clinica No 1268, p 10), and has continued its expansion with the acquisition of the Owings Mills, Maryland-headquartered diagnostic test kits provider. SurModics will pay $11.3m at the closing of the deal, and a potential $11.4m in revenue targets at future dates. This transaction will provide the firm with entry into the in vitro diagnostic tests market, which was worth approximately $32bn in 2005.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.